Gabriel Harnier - Bayer Aktiengesellscha Patents Law
| BAYA Stock | EUR 4.96 0.04 0.80% |
Insider
Gabriel Harnier is Patents Law of Bayer Aktiengesellschaft
| Age | 52 |
| Phone | 49 214 30 1 |
| Web | https://www.bayer.com |
Bayer Aktiengesellscha Management Efficiency
The company has return on total asset (ROA) of 0.0576 % which means that it generated a profit of $0.0576 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.13 %, meaning that it generated $0.13 on every $100 dollars invested by stockholders. Bayer Aktiengesellscha's management efficiency ratios could be used to measure how well Bayer Aktiengesellscha manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Frank Lohner | Amgen Inc | 54 | |
| Peter Dannenbaum | Merck Co | N/A | |
| Murdo Gordon | Amgen Inc | 56 | |
| Collette Taylor | Astellas Pharma | 60 | |
| Cristina Wilbur | Roche Holding Ltd | 56 | |
| Jonathan Graham | Amgen Inc | 62 | |
| Jennifer Mauer | Merck Co | N/A | |
| Kenneth Frazier | Merck Co | 67 | |
| Catherine Levitt | Astellas Pharma | N/A | |
| Caroline Litchfield | Merck Co | 54 | |
| Kenji Yasukawa | Astellas Pharma | 63 | |
| Nobue Yasuda | Astellas Pharma | N/A | |
| Esteban Santos | Amgen Inc | 55 | |
| William Anderson | Roche Holding Ltd | 57 | |
| Alan Hippe | Roche Holding Ltd | 56 | |
| Minoru Kikuoka | Astellas Pharma | N/A | |
| Pascale Schmidt | Roche Holding Ltd | 50 | |
| Cristal Downing | Merck Co | 54 | |
| Robert Bradway | Amgen Inc | 60 | |
| Thomas Schinecker | Roche Holding Ltd | 48 | |
| David MD | Amgen Inc | 60 | |
Management Performance
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0576 |
Bayer Aktiengesellschaft Leadership Team
Elected by the shareholders, the Bayer Aktiengesellscha's board of directors comprises two types of representatives: Bayer Aktiengesellscha inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bayer. The board's role is to monitor Bayer Aktiengesellscha's management team and ensure that shareholders' interests are well served. Bayer Aktiengesellscha's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bayer Aktiengesellscha's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sarena Lin, Labor Officer | ||
| Oliver Maier, Head Relations | ||
| Gabriel Harnier, Patents Law | ||
| Heiko Schipper, Member Division | ||
| Rodrigo Santos, Member Division | ||
| Michael Preuss, Gov Communications | ||
| Stefan Oelrich, Head Management | ||
| Wolfgang Nickl, CFO Board | ||
| BerndPeter Bier, Head Taxes | ||
| Werner Baumann, CEO Board |
Bayer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bayer Aktiengesellscha a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0576 | |||
| Current Valuation | 82.93 B | |||
| Shares Outstanding | 3.93 B | |||
| Shares Owned By Institutions | 0.10 % | |||
| Price To Earning | 12.22 X | |||
| Price To Book | 1.32 X | |||
| Price To Sales | 1.00 X | |||
| Revenue | 44.08 B | |||
| Gross Profit | 30.87 B |
Currently Active Assets on Macroaxis
Other Information on Investing in Bayer Stock
Bayer Aktiengesellscha financial ratios help investors to determine whether Bayer Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bayer with respect to the benefits of owning Bayer Aktiengesellscha security.